Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy

Nephron

Volumn 72, Issue 2, 1996, Pages 150-154

  Rapoport, Jayson ^a   Mostoslavski, Marcus ^b   Ben David, Aharon ^a   Knecht, Aharon ^a   Blau, Alexander ^a   Arad, Jacob ^a   Zlotnik, Moshe ^b   Chaimovitz, Cidio ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

1 Hydroxycholecalciferol; Hemodialysis; Hypercalcemia; Hyperparathyroidism; Pulse therapy

Indexed keywords

COLECALCIFEROL DERIVATIVE; HYDROXYCOLECALCIFEROL; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; LETHARGY; MALE; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RESTLESSNESS; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CALCIUM; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 0030052346     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188833     Document Type: Article

References (18)

1. Malluchc H, Faugcre M-C: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 1990:38:193-211.
2. Hutchison AJ. Whitehouse RW. Boulton HF. Adams JE. Mawer EB. Frecmont TJ. Gokal R: Correlation of bone histology with parathyroid hormone, vitamin Dj, and radiology in end-stage renal disease. Kidney Int 1993:44:1071-1077.
3. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985:83:4270-4273.
4. Slatopolsky E, Wccrts C, Thielan J, Horst R. Harter H. Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxychole-calciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
5. Tsukamoto Y, Nomura M, Marumo F: Pharmacological parathyroidectomy by oral l,25[OH]jD? pulse therapy. Nephron 1989:51: 130-131.
6. Tsukamoto Y. Nomura M, Takahashi Y. et al: The ‘oral 1,25-dihydroxyvitamin Di pulse therapy’ in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57:23-28.
7. Muramoto H. Haruki K, Yoshimura A, et al: Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of l,25[OH]2 vitamin D3. Nephron 1991:58:288-294.
8. Klaus G. Mehls O. Hinderer J. Ritz E: Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 1991: 337:800-801.
9. Felsenfeld AJ. Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 1993: 43:771-789.
10. Berl T. Berns AS. Huffcr WE. et al: 1,25-Dihy-droxvcholecalciferol effects in chronic dialysis: A double-blind controlled study. Ann Intern Med 1978:88:774-780.
11. Reichel H. Szabo A. Uhl J. Pesian S. Schmutz A. Schmidt-Gayk H. Ritz E: Intermittent versus continuous administration of dihvdroxyvi-tamin D in experimental renal hyperparathyroidism. Kidney Int 1993;44:1259-1265.
12. Herrmann P. Ritz E. Schmidt-Gayk H. et al: Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 1994;67:48-53.
13. Kimura Y. Nakayama M. Kuriyama S, Wata-nabe S. Kawaguchi Y. Sakai O: Pharmakokine-tics of active vitamins D3, la-hydroxyvitamin D3 and la,25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol 1991;35:72-77.
14. Schaefer K. Umlauf E. von Herrath D: Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992;19:460-464.
15. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomav D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994:45:1710-1721.
16. McCarron DA, Muther RS, Lcnfesty B, et al: Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 1982:22:662-670.
17. Quarles LD, Davidai GA, Schwab SJ, et al: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 1988:34:840-844.
18. Fukuda N. Tanaka H. Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993:92:1436-1443.